A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants With Advanced Solid Tumors
Latest Information Update: 25 Sep 2025
At a glance
- Drugs SIM-0505 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Jiangsu Simcere Pharmaceutical; NextCure
Most Recent Events
- 22 Aug 2025 Planned number of patients changed from 172 to 414.
- 12 Mar 2025 Status changed from not yet recruiting to recruiting.
- 30 Jan 2025 Status changed from planning to not yet recruiting.